Pharmafile Logo
Pharmafocus logo
Advanced Search

prostate cancer

Showing 15 posts of 92 posts found.

Insider Interview: Paving paths in prostate cancer

May 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Interview, Janssen, feature, pharma, prostate cancer

Joaquin Casariego Garcia Luben, Medical Affairs Director Europe, Middle East & Africa, Prostate Cancer for Johnson & Johnson (pictured) discusses …

Feature

NICE turns down Astellas’ Xtandi in prostate cancer

April 8, 2019
Research and Development, Sales and Marketing Astellas, Cancer, NHS, NICE, UK, pharma, prostate cancer

Astellas’ Xtandi (enzalutamide) has been rejected by UK medicines watchdog NICE for use on the NHS as a therapy for …

News

Astellas’ Xtandi “significantly improves” progression-free survival in advanced hormone-sensitive prostate cancer

February 18, 2019
Research and Development, Sales and Marketing Astellas, Cancer, Xtandi, pharma, prostate cancer

Japanese pharma firm Astellas has lifted the curtain on new data for its androgen receptor signalling inhibitor Xtandi (enzalutamide), when …

News
janssen_latest_logo_on_sign

Janssen’s Erleada meets primary endpoints in ongoing trial into metastatic castration-sensitive prostate cancer

January 31, 2019
Research and Development Cancer, Erleada, Janssen, pharma, prostate cancer

Janssen has revealed that its androgen receptor (AR) inhibitor Erleada (apalutamide), in combination with androgen deprivation therapy (ADT), has been …

News
787px-prostate_normal_1

Prostate cancer researchers win $2m to explore carboplatin therapy

November 7, 2018
Research and Development Cancer, carboplatin therapy, prostate cancer

The US Department of Defence has awarded a coalition of researchers – made up of the Prostate Cancer Clinical Research …

News

FDA expands Pfizer and Astellas’ Xtandi into castration-resistant prostate cancer

July 16, 2018
Sales and Marketing Astellas, Cancer, FDA, Pfizer, US, Xtandi, pharma, prostate cancer

Astellas and Pfizer have revealed that their androgen receptor inhibitor Xtandi (enzalutamide) has received approval from the FDA to expand …

News
shutterstock_349943306

Sophiris halts cancer study after patient death

June 25, 2018
Research and Development, Sales and Marketing Cancer, Sophiris, pharma, prostate cancer

Another clinical trial has been forced to a standstill as biotech firm Sophiris revealed that a patient death had prompted …

News
astrazeneca_sign_sky

AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer

June 5, 2018
Research and Development ASCO, AstraZeneca, Cancer, MSD< pharma, Merck, lynparza, prostate cancer

In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its …

News
doctor_notes

Keytruda offers significant hope in subset of prostate cancer

June 4, 2018
Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical, prostate cancer

Up until present, no studies had shown that immunotherapies could offer potential treatment for men with prostate cancer; however, at …

News
fda2outsideweb

Sun Pharma drug combo scores FDA approval in advanced castration-resistant prostate cancer

May 23, 2018
Research and Development, Sales and Marketing Cancer, Churchill Pharmaceuticals, FDA, Sun Pharma, US, Yonsa, pharma, prostate cancer

Sun Pharma is celebrating with the announcement that its CYP17 inhibitor Yonsa (abiraterone acetate) has been awarded FDA approval in …

News
theresa_may_-_credit_arno_mikkor

May announces £75m prostate cancer boost

April 10, 2018
Manufacturing and Production, Medical Communications Prostate Cancer UK, UK, biotech, drugs, pharma, pharmaceutical, prostate cancer

Prostate cancer has begun to receive more publicity in recent years in the UK, but not for the right reasons. …

News
800px-prostate_cancer_1

Almost 40% of UK prostate cancer cases are diagnosed late, according to report

April 9, 2018
Medical Communications, Research and Development, Sales and Marketing Cancer, UK, pharma, prostate cancer

A report conducted by charity Orchid has revealed a “worrying trend” in the treatment of prostate cancer, indicating that as …

News
mri_credit_-_ptrump16

NHS trials “world-leading” initiative to cut prostate cancer diagnoses to just days

March 5, 2018
Research and Development, Sales and Marketing Cancer, MRI, NHS, pharma, prostate cancer

The NHS has revealed plans to cut the average diagnosis times for prostate cancer from six weeks to less than …

News
jj

J&J’s apalutamide scores snap FDA approval in castration-resistant prostate cancer subgroup

February 15, 2018
Sales and Marketing Cancer, Erleada, FDA, J&J, JJ, Johsnon & Johnson, apalutamide, pharma, prostate cancer

Johnson & Johnson has announced that its androgen receptor inhibitor apalutamide, now branded as Erleada, has received approval from the …

News

J&J’s apalutamide shows strength in non-metastatic prostate cancer

February 7, 2018
Research and Development J&J, JJ, Johnson & Johnson, pharma, prostate cancer

Johnson & Johnson unveiled new data at the ASCO Genitourinary Cancer symposium which demonstrated that its androgen receptor antagonist apalutamide …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025